FDA Clears Multi-Patient CT Injection System from Bayer
Facilitating optimal use of contrast, the Medrad Centargo CT Injection System reportedly combines user-friendly features with workflow efficiency for high-volume CT departments.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the Medrad Centargo CT Injection System, which enables contrast administration for multiple patients undergoing computed tomography (CT) exams.
Featuring a pre-assembled Day Set and a snap-in patient line that auto-primes upon insertion, the Medrad Centargo CT Injection System allows contrast set-up for multiple patients to be completed in less than two minutes, according to Bayer, the manufacturer of the Medrad Centargo CT Injection System.
The newly FDA-cleared Medrad Centargo CT Injection System reportedly allows contrast set-up for multiple patients to be completed in less than two minutes. (Photo courtesy of Bayer.)
For demanding CT protocols, Bayer said the system also has a Dual Flow feature that allows simultaneous administration of contrast and saline, which is facilitated by the Medrad Centargo CT Injection System’s piston-based technology.
The combination of automated documentation software and the system’s integrated barcode reader enables simplified access to contrast and injection details to help streamline reporting.
“We know radiologists today are facing a continuously increasing workload, and the automation, integration and mobility of the Medrad® Centargo CT Injection System helps radiology staff do more with less, allowing them more time to focus on their patients,” noted Sven Schmidt, the head of Region Americas Radiology at Bayer.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
